EXECUTIVE ENGAGEMENTS
POOL
INTERACTIONS
PARTICIPANTS
VALIDATIONS
COMPANIES
* Login for a full stack data experience
DATE
JAN 2023
TABLES
122
PAGES
186
EDITION
16
PRICE
USD 5600
CODE
MCP-6195
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
What`s New for 2023?
»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
»Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
»Online interactive peer-to-peer collaborative bespoke updates
»Access to our digital archives and MarketGlass Research Platform
»Complimentary updates for one year
Looking Ahead to 2023
The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market to Reach $51.9 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics estimated at US$65.6 Billion in the year 2022, is projected to reach a revised size of US$51.9 Billion by 2030, growing at aCAGR of -2.9% over the period 2022-2030. Stimulant, one of the segments analyzed in the report, is projected to record -3.2% CAGR and reach US$43 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Non-Stimulant segment is readjusted to a revised -1.1% CAGR for the next 8-year period.
The U.S. Market is Estimated at $19.5 Billion, While China is Forecast to Grow at -3.3% CAGR
The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics market in the U.S. is estimated at US$19.5 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$9 Billion by the year 2030 trailing a CAGR of -3.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at -3.5% and -3.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately -4.2% CAGR.
SELECT PLAYERS
Alcobra Ltd.; Amarantus Bioscience Holdings, Inc.; Curemark, LLC; Eli Lilly and Company; Intellipharmaceutics International, Inc.; Janssen Global Services, LLC; Mallinckrodt PLC; Mylan NV; Neos Therapeutics, Inc.; Neurovance, Inc.; Noven Pharmaceuticals, Inc.; Pfizer Inc.; Shire plc; Supernus Pharmaceuticals, Inc.; Tris Pharma, Inc.
SEGMENTS
» Drug Type (Stimulant, Non-Stimulant) » Demography (Adult, Children) » Distribution Channel (Retail Pharmacy, Hospital Pharmacy)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Influencer Market Insights |
World Market Trajectories |
ADHD Therapeutics: A Primer |
Recent Market Activity |
ADHD Therapeutics Market Outlook |
Factors Driving ADHD Therapeutics Market |
Changes in Insurance Coverage |
Addition of Formal Guidelines |
Low Diagnosis Threshold |
Advancements in Field of Medicine |
Unmet Needs |
Launch of Pipeline Drugs |
Factors Inhibiting ADHD Therapeutics Market |
Side Effects Related to Use of Stimulants to Treat ADHD |
Under-diagnosis of ADHD Condition |
Reduced Availability of Non-Stimulants in Certain Geographies |
Competitive Landscape |
Major ADHD Medications Available in the Market |
ADHD Medications Approved by FDA |
Patent Validity for Major ADHD Drugs |
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics – Global Key Competitors Percentage Market Share in 2022 (E) |
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) |
Impact of Covid-19 and a Looming Global Recession |
2. FOCUS ON SELECT PLAYERS |
Alcobra Ltd. (Israel) |
Amarantus Bioscience Holdings, Inc. (US) |
Amedra Pharmaceuticals LLC (US) |
Curemark, LLC. (US) |
Eli Lilly and Company (US) |
Intellipharmaceutics International, Inc. (US) |
Janssen Global Services, LLC (US) |
Mallinckrodt PLC (Ireland) |
Mylan N.V. (The Netherlands) |
Neos Therapeutics, Inc. (US) |
Neurovance, Inc. (US) |
Noven Pharmaceuticals, Inc. (US) |
Pfizer Inc. (US) |
Shire plc (Ireland) |
Supernus Pharmaceuticals, Inc. (US) |
Tris Pharma, Inc. (US) |
3. MARKET TRENDS & DRIVERS |
Biological Psychiatry Gaining Ground |
Social Media Drives Heightened Awareness |
Stimulants Dominate the Market but Non-Stimulants Inching Their Way to Popularity |
Robust Growth in Pediatric ADHD Therapeutic Market to Propel Overall Market |
Strategic Alliances |
4. GLOBAL MARKET PERSPECTIVE |
World Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Stimulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Stimulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Stimulant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Non-Stimulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Non-Stimulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Non-Stimulant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Adult by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Children by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Children by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Children by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
World Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2012 through 2027 |
III. MARKET ANALYSIS |
UNITED STATES |
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E) |
USA Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
USA Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
USA 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2012, 2021 & 2027 |
USA Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
USA Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
USA 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2012, 2021 & 2027 |
USA Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
USA Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
USA 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2012, 2021 & 2027 |
CANADA |
Canada Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Canada Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Canada 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2012, 2021 & 2027 |
Canada Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Canada Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Canada 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2012, 2021 & 2027 |
Canada Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Canada Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Canada 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2012, 2021 & 2027 |
JAPAN |
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E) |
Japan Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Japan Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Japan 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2012, 2021 & 2027 |
Japan Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Japan Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Japan 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2012, 2021 & 2027 |
Japan Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Japan Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Japan 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2012, 2021 & 2027 |
CHINA |
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E) |
China Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
China Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
China 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2012, 2021 & 2027 |
China Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
China Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
China 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2012, 2021 & 2027 |
China Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
China Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
China 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2012, 2021 & 2027 |
EUROPE |
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E) |
Europe Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027 |
Europe Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2012, 2021 & 2027 |
Europe Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2012, 2021 & 2027 |
Europe Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2012, 2021 & 2027 |
FRANCE |
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E) |
France Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
France Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
France 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2012, 2021 & 2027 |
France Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
France Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
France 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2012, 2021 & 2027 |
France Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
France Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
France 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2012, 2021 & 2027 |
GERMANY |
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E) |
Germany Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Germany Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Germany 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2012, 2021 & 2027 |
Germany Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Germany Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Germany 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2012, 2021 & 2027 |
Germany Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Germany Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Germany 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2012, 2021 & 2027 |
ITALY |
Italy Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Italy Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Italy 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2012, 2021 & 2027 |
Italy Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Italy Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Italy 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2012, 2021 & 2027 |
Italy Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Italy Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Italy 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2012, 2021 & 2027 |
UNITED KINGDOM |
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E) |
UK Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
UK Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
UK 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2012, 2021 & 2027 |
UK Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
UK Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
UK 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2012, 2021 & 2027 |
UK Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
UK Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
UK 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2012, 2021 & 2027 |
REST OF EUROPE |
Rest of Europe Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of Europe 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2012, 2021 & 2027 |
Rest of Europe Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of Europe 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2012, 2021 & 2027 |
Rest of Europe Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of Europe 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2012, 2021 & 2027 |
ASIA-PACIFIC |
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E) |
Asia-Pacific Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2012, 2021 & 2027 |
Asia-Pacific Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2012, 2021 & 2027 |
Asia-Pacific Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2012, 2021 & 2027 |
REST OF WORLD |
Rest of World Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of World Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of World 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2012, 2021 & 2027 |
Rest of World Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of World Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of World 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2012, 2021 & 2027 |
Rest of World Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of World Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of World 15-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2012, 2021 & 2027 |
IV. COMPETITION |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com